A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients

HIV-1 Infection Clinical Trial

Official title:

A Proof of Concept, Multiple Dose-Escalating Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01092104
• Other study ID #: 652-2-201
• Status: Completed
• Phase: Phase 1/Phase 2
• First received: March 22, 2010
• Last updated: July 3, 2013
• Start date: February 2009
• Est. completion date: November 2009

Study information

• Verified date: July 2013
• Source: Tobira Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

A double-blind, randomized, placebo-controlled, dose-escalating study to assess the antiviral activity, safety, tolerability, and pharmacokinetics (PK) of the CCR5 antagonist TBR 652 monotherapy dosed orally once daily (QD) for 10 days in HIV 1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naïve patients.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 52
• Est. completion date: November 2009
• Est. primary completion date: November 2009
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. No clinically significant findings on Screening evaluations (clinical, laboratory, and ECG), which in the opinion of the Investigator would interfere with the subject's ability to comply with the protocol.

2. Antiretroviral treatment-experienced; no antiretroviral therapy for at least 6 weeks prior to study entry.

3. CCR5 antagonist therapy naive.

4. CD4 cell count >/= 250 cells/mm3 during Screening (within 30 days prior to first dose).

5. Two separate qualifying plasma HIV 1 RNA levels >/= 5,000 copies/mL within 45 days prior to first dose.

6. Females who are not of reproductive potential (documented to be surgically sterile or postmenopausal [defined as amenorrhea = 1 year and follicle stimulating hormone {FSH} = 30 mU/mL]).

7. Females of child-bearing potential may be enrolled following a negative serum pregnancy test. If participating in activity that could lead to pregnancy, males and females shall agree to use two forms of barrier method contraception during the trial and for 2 months after stopping the medication.

Exclusion Criteria:

1. Presence of CXCR4- or dual/mixed-tropic HIV 1 virus.

2. Active CDC category C disease (except cutaneous Kaposi's sarcoma not requiring systemic therapy during the trial).

3. History of infection with hepatitis B or hepatitis C virus, history of cirrhosis, or any known active or chronic liver disease. NOTE: Hepatitis B vaccinated patients are eligible.

4. Serum ALT or AST values greater than Grade 1 or bilirubin values greater than the upper limit of normal (ULN) at Screening.

5. History of HIV-2.

6. Recent history (< 30 days prior to study drug administration) of clinically significant infection.

7. Pregnant females or females who are breastfeeding.

8. Treatment with immunomodulating agents (such as systemic corticosteroids, interleukins, interferons) or any agent with known anti-HIV activity within 30 days prior to study drug administration.

9. Treatment with any vaccine within 30 days of study drug administration.

10. A positive pre-study drug screen, including amphetamines, barbiturates, cocaine, or PCP.

11. Anticipated use of antacids during the trial and/or within 7 days prior to first dose of study drug.

12. Current alcohol or drug use, which in the expert judgment of the investigator, will interfere with the patient's ability to comply with the protocol requirements.

13. Inability, in the opinion of the investigator, to comply with the dosing schedule and protocol evaluations.

14. Use of any experimental medications within 4 weeks prior to Screening.

15. Current (within 30 days prior to the first dose of study drug) or anticipated use of antimetabolites; alkylating agents; or drugs, herbal preparations, and foods (including grapefruit) known to affect the CYP 3A4 or CYP 2C8 enzymes or P-glycoprotein transporters.

16. History of clinically significant hepatic, metabolic, endocrine, renal, hematologic, pulmonary, gastrointestinal, or cardiovascular disorders (including ECG abnormalities).

17. Uncontrolled hypertension.

18. Presence of a malabsorption syndrome affecting drug absorption (e.g., Crohn's disease, chronic pancreatitis).

19. History of malignancy with exception of cured basal or squamous cell carcinoma of the skin.

20. Receipt of radiation or cytotoxic chemotherapeutic agents and not recovered from side effects prior to the first dose of study medication.

21. Subjects who have used any over-the-counter medications (including phytotherapeutic, herbal, or plant-derived preparations) within 14 days prior to the first dose of study medication, unless approved by the Investigator, or who have used St. John's wort within 21 days prior to the first dose of study drug. (St. John's wort is prohibited during the study.)

22. History or presence of an abnormal ECG.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• HIV-1 Infection

Intervention

Drug:
• TBR-652
TBR-652 25 mg
• TBR-652 Matching Placebo
Matching Placebo
• TBR-652 50 mg
TBR-652 50 mg QD for 10 days
• TBR-652 75 mg
TBR-652 75 mg QD for 10 days
• TBR-652 100 mg
TBR-652 100 mg QD for 10 days
• TBR-652 150 mg
TBR-652 150 mg QD for 10 days

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Tobira Therapeutics, Inc.

References & Publications (2)

Lalezari J, Gathe J, Brinson C, Thompson M, Cohen C, Dejesus E, Galindez J, Ernst JA, Martin DE, Palleja SM. Safety, efficacy, and pharmacokinetics of TBR-652, a CCR5/CCR2 antagonist, in HIV-1-infected, treatment-experienced, CCR5 antagonist-naive subject — View Citation

Marier JF, Trinh M, Pheng LH, Palleja SM, Martin DE. Pharmacokinetics and pharmacodynamics of TBR-652, a novel CCR5 antagonist, in HIV-1-infected, antiretroviral treatment-experienced, CCR5 antagonist-naïve patients. Antimicrob Agents Chemother. 2011 Jun; — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	HIV-1 RNA Change from Baseline		10 days	No